MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

CARTITUDE-2 is a phase 2 multicohort study evaluating ciltacabtagene autoleucel (cilta-cel), including cilta-cel ± lenalidomide maintenance in patients with newly diagnosed multiple myeloma (NDMM) with

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-09, Vol.24, p.S564-S565
Main Authors: Arnulf, Bertrand, Kerre, Tessa, Agha, Mounzer, Delforge, Michel, Braunschweig, Ira, Shah, Nishi, Richard, Shambavi, Alsina, Melissa, Einsele, Hermann, Mistry, Pankaj, Varsos, Helen, Corsale, Christina, Schecter, Jordan, De Braganca, Kevin, Jethava, Yogesh, Song, Qingxuan, Koneru, Mythili, Akram, Muhammad, Cohen, Yaël, Roeloffzen, Wilfried
Format: Article
Language:English
Subjects:
ciltacabtagene autoleucel
lenalidomide
multiple myeloma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CARTITUDE-2 is a phase 2 multicohort study evaluating ciltacabtagene autoleucel (cilta-cel), including cilta-cel ± lenalidomide maintenance in patients with newly diagnosed multiple myeloma (NDMM) with
ISSN:2152-2650
DOI:10.1016/S2152-2650(24)01694-X